Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMVP released Phase 2 interim data on rezatapopt's efficacy. Overall response rate was 33% across multiple solid tumor types. Ovarian cancer had the highest response rate at 43%. Plans to submit NDA for ovarian cancer by Q1 2027. Stock dropped 23.30% to $1.23 following the announcement.
View signal analysis